Fairvalue-Calculator Fairvalue-Calculator
EN DE

WOOJUNG BIO, Inc (215380) Fair Value & Analysis

Healthcare · KR · Market cap 42.2B KRW

Price2,220 KRW
Fair Value2,524 KRW
Upside+13.7%
Quality95/100
Evidence: Low Range 1,893 KRW – 3,155 KRW

Fair value as of: Jun 24, 2026

Analysis

WOOJUNG BIO, Inc (215380) currently trades at 2,220 KRW, while our model-based Fair Value estimate is 2,524 KRW — implying the stock looks roughly 13.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

WOOJUNG BIO, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and environmental monitoring, and technical support services. In addition, It offers construction and implementation, infection control, maintenance, laboratory and pharmaceutical equipment, and consumables and animal resourcing services. The company was founded in 1989 and is based in Hwaseong-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is WOOJUNG BIO, Inc (215380) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2,524 KRW versus a price of 2,220 KRW — about +14% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 215380?
Our 21-model fair value for WOOJUNG BIO, Inc is 2,524 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 2,220 KRW.
What is the quality score of 215380?
WOOJUNG BIO, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.